TITLE

Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD

PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroids reduce the progression of airflow limitation. Inhaled corticosteroids (ICS) slow the progression of airflow limitation in COPD Studies were selected if they were full reports of randomized controlled trials of ICSs in patients with COPD, had 1 year of follow-up, examined change in FEV [sub 1] over time, patients with asthma were excluded, and patients were studied when COPD was stable. The ICSs studied were fluticasone, triamcinolone, budesonide, and beclomethasone.
ACCESSION #
13221816

 

Related Articles

  • Using exhaled NO concentrations to adjust inhaled corticosteroid dose maintained asthma control and reduced the dose. Smith, A. D.; Cowan, J. O.; Brassett, K. P.; Taylor, R. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article reports on a study to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic asthma. Patients aged 12-75...

  • Commentary. Rees, P. John // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article comments on a study by A. D. Smith and colleagues to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic...

  • Review: Inhaled corticosteroids slow the progression of airflow limitation in COPD: COMMENTARY. Greenstone, Michael // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p57 

    Chronic obstructive pulmonary disease (COPD) is largely a disease of vulnerable smokers in whom the normal age-related decline in lung function is accelerated from a mean of 30 mL/y to 60 mL/y. Unlike asthma, the airflow obstruction and airway inflammation of COPD respond poorly to...

  • EDITORS' CHOICE. Stephenson, Paul; Sheikh, Aziz // Primary Care Respiratory Journal;Mar2013, Vol. 22 Issue 1, piii 

    An introduction is presented in which the editors discuss various reports within the issue on topics including the risk and benefit of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary disease (COPD) by Price and colleagues, trend in age-adjusted prevalence of...

  • Step One for Asthma Treatment: β-Agonists or Inhaled Corticosteroids? Redington, A.E. // Drugs;Jul2001, Vol. 61 Issue 9, p1231 

    Inhaled corticosteroids have proven effectiveness in chronic persistent asthma and are now recommended as first-line therapy in this condition. In contrast, long term preventative therapy is not currently considered necessary for patients with disease that is only mild and episodic. Recently,...

  • Poor reporting may infer poor science: lessons learned from asthma trials. Been, Jasper V.; Kotz, Daniel; van Schayck, Onno C. P. // Primary Care Respiratory Journal;Dec2013, Vol. 22 Issue 4, p388 

    The article presents the author's views on asthma trials. The author states that there is considerable room for improvement in clinical trial reporting quality. It is also stated that although randomised controlled trial (RCT) is the gold standard for research, methodology or trial processes...

  • Lower Corticosteroid Skin Blanching Response Is Associated with Severe COPD. Hoonhorst, Susan J. M.; ten Hacken, Nick H. T.; Lo Tam Loi, Adèle T.; Koenderman, Leo; Lammers, Jan Willem J.; Telenga, Eef D.; Boezen, H. Marike; van den Berge, Maarten; Postma, Dirkje S. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by ongoing inflammatory and remodeling processes of the airways and lung tissue. Inflammation can be targeted by corticosteroids. However, airway inflammation is generally less...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics